Covidien wins judicial OK for labor lawsuit class action settlement; Allergan's Q4 revenue climbs higher;

@FierceMedDev: Edwards wins wider use for older model Sapien heart valve in Europe. More | Follow @FierceMedDev

@MarkHFierce: Thoratec's HeartMate revenue growth is certainly not what it once was. Story | Follow @MarkHFierce

@MichaelGFierce: Check out today's special report: The top drug delivery partnerships of 2013. Report from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: CVS takes cigarettes off the shelf, despite projected dip in profits. Article | Follow @EmilyWFierce

> Covidien ($COV) wants to pay $2.5 million to settle a class action lawsuit that accused it of pressuring workers not to take breaks, and a California judge has signed off on the agreement. Story

> Medtronic's ($MDT) scientists and engineers in Tempe, AZ, are behind development in what would be the world's smallest pacemaker, a vitamin-sized device that just began global clinical trials. Story

> Allergan ($AGN), which produces eye care products, breast implants and a number of other medical devices and drugs, said its fourth-quarter revenue climbed 14%. Story (subs. req.)

> Haemonetics ($HAE), a Massachusetts maker of blood collection and other med tech-related products, will hold its annual investor and analyst meeting on Tuesday, May 20. Item

> In a regional first for North and South Carolina, doctors at Carolinas HealthCare System say they've implanted a total artificial heart in a 49-year-old male patient. SynCardia makes the FDA-approved device. Story

Biotech News

@FierceBiotech: Purdue launches $12M tit-for-tat fund to seed new biotechs . More | Follow @FierceBiotech

@JohnCFierce: We're seeing a mix of upsized IPO successes with some disappointments as well. Seems the theme for biotech's Q1 biotech. More | Follow @JohnCFierce

@DamianFierce: In the next two years, $GSK expects 6 PhIII readouts and 10 PhIII starts. Release | Follow @DamianFierce

@EmilyMFierce: A new strain of avian flu in China has killed one woman and infected at least one another. Story via Washington Post | Follow @EmilyMFierce

> Merck loops Pfizer, Amgen and Incyte in on MK-3475 immunotherapy deal spree. News

> GlaxoSmithKline reloads its pipeline with new PhIII drugs following approvals, setbacks. Story

Pharma News

@FiercePharma: New chief expands Novo team for stepped-up assault on U.S. diabetes market. Story | Follow @FiercePharma

@TracyStaton: Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. Report | Follow @TracyStaton

@EricPFierce: My colleague Mark Hollmer offers a thoughtful analysis of pacemakers after having one put in. Check it out. More | Follow @EricPFierce

> Novartis vaccine unit is no wallflower: It has suitors flirting with a deal, too. More

> Merck's earnings miss slightly but it was not the 'mega-miss' some anticipated. Story

> Gilead sales leap 21%, thanks to fast-growing HIV pills Stribild, Complera. Report

Drug Delivery News

> The top drug delivery partnerships of 2013. Special Report

> Oramed touts PhIIa insulin pill study results; analysts say 'Prove it.' Story

> Microchip coated with cells gives insight into nanoparticle penetration. Article

> Regulus renews Sanofi microRNA pact to focus on orphan, cancer treatments. Story

> Novo Nordisk taps Zosano's microneedle patch for diabetes drug delivery. News

> Pfizer snags electroporation device license from Ichor for cancer vaccine delivery. News

Diagnostics News

> Israeli team finds that diabetes Dx can also screen for at-risk patients. Story

> Myriad Genetics jumps into RA Dx with its $270M Crescendo Bioscience deal. News

> Loyola team zeroes in on two biomarkers linked to an infant bowel disorder. Article

> Thermo Fisher's revenue climbs as U.S. regulators clear $13.6B Life Tech buy. Story

> NeoGenomics' 22 cancer tests hit the market. Item

> The next possible stroke biomarker might be oxidized LDL. Story

Pharma Marketing News

> Digital agencies use ice cream, quirky tees to woo talent away from rivals. Item

> New chief expands Novo team for stepped-up assault on U.S. diabetes market. News

> How fast can Gilead's hep C star go from zero to $6 billion? Story

> That drug's got personality. But is it 'original,' 'dependable' or both? Article

> As doctors get device-happy, reaching them is a 3-pronged strategy. Story

> UCB nabs Asian marketing rights to hot Biogen MS drugs. News

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.